Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389805 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00389805 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 27 participants.
The verdict
NCT00389805, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of bortezomib when given together with pemetrexed disodium and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- GENETIC mutation analysis
- DRUG bortezomib
- DRUG pemetrexed disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389805
The ClinicalTrials.gov registry entry for NCT00389805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00389805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389805 about?
NCT00389805 is a clinical study titled "Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors". RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two di...
What is the current status of trial NCT00389805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2005-03. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00389805?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), mutation analysis (GENETIC), bortezomib (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00389805?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.